Skip to main content

Article Category


Article available in the folowing languages:

Largest-ever IMI Immunology Project 3TR: Accelerating Precision Medicine for Immune-Mediated Diseases

The 80 million euro public-private partnership project aims to improve disease management of non-responders to therapy. In a never-before-seen effort 3TR brings together renowned experts from 69 partners, including academic institutions, industrial companies, SMEs and patient organisations covering 15 European countries.The interdisciplinary consortium will explore the mechanisms of non-response to treatment within and across seven different immune-mediated diseases in the coming seven years.


Autoimmune, inflammatory and allergic diseases are common chronic diseases that significantly affect the wellbeing of millions of people around the globe and pose a substantial burden to healthcare systems. While different treatments are available, response and disease progression in individual patients remain unpredictable. In order to be able to better predict treatment response and potentially identify novel biomarkers leading to improved patient management and personalised therapy, a deeper understanding of the cellular mechanisms driving disease development is urgently needed. 3TR sets out to fundamentally increase our knowledge of the molecular pathways and mechanisms linked to response and non-response to therapy in seven different immune-mediated, allergic and inflammatory diseases: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (incl. ulcerative colitis and Crohn's disease), asthma, and chronic obstructive pulmonary disease. Despite their heterogeneity, recent studies have shown that on the molecular level certain patterns are shared by patients across these diseases, thus suggesting they may also share pathways of response to treatment and disease progression. "For the first time, the 3TR team will align and integrate the analysis of autoimmune, allergic, and inflammatory conditions to identify the relationship between longitudinal molecular and microbiome profiles in blood cells and tissues, and disease paths. In a unique approach we will study the seven diseases both in parallel and jointly," explains Marta Alarcón-Riquelme, scientific coordinator of 3TR and Head of Medical Genomics at the GENYO centre at the Fundación Pública Andaluza Progreso y Salud. "We believe that this high-resolution multi-omics profiling analysis of individualised response to treatment and disease progression will facilitate stratification and identification of molecular patterns that better predict response or non-response to therapy. This comprehensive approach will help identify biomarkers to improve patient management within these diseases." Frank Nestle, MD, Sanofi's head of research in immunology and inflammation, adds: "This consortium is focused on addressing unmet treatment needs for many of the immunological and inflammatory conditions covered in this initiative. 3TR will provide the unique opportunity to investigate a considerable amount of clinical and molecular data across important inflammatory disease categories including treatment responders and non-responders. As scientific project lead of 3TR, Sanofi is confident that this public-private partnership will bring valuable insights to help in the discovery of more effective treatment options for people living with chronic inflammatory conditions." A centralised data management platform will enable detailed and comprehensive, state-of-the-art bioinformatics and biostatistics analyses. "3TR has great potential to transform and significantly enhance the management of patients with chronic inflammatory diseases by introducing a scientific evidence-based rationale for treatment selection, rather than following the traditional trial and error approach. This will increase therapeutic success, reduce risks of avoidable side effects in patients unlikely to benefit from the drug they are prescribed, reduce health care costs, but above all: improve the patient's quality of life," underlines Dr Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI). The 3TR team will officially kick off their activities with a first meeting in Granada, Spain from 30-31 October 2019. 3TR has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant Agreement No 831434. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.


Precision Medicine, Immune-mediated diseases, 3TR, Health, Asthma, COPD, Multiple Sclerosis, Systemic Lupus Erythematosus, Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Genetics